医疗保险报销与生物制剂的使用：激励措施、可及性、公共利益及最佳医疗服务 - Suppr

Suppr

超能文献

Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care.

作者信息

Ward Michael M

出版信息

Arthritis Care Res (Hoboken). 2010 Mar;62(3):293-5. doi: 10.1002/acr.20088.

DOI:10.1002/acr.20088

PMID:20391473

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3018780/

Abstract

摘要

相似文献

Medicare reimbursement and the use of biologic agents: incentives, access, the public good, and optimal care.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):293-5. doi: 10.1002/acr.20088.

Impact of the Medicare Modernization Act of 2003 on utilization and spending for medicare part B-covered biologics in rheumatoid arthritis.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):354-61. doi: 10.1002/acr.20010.

'B' isn't always for biologics.

Manag Care. 2012 Feb;21(2):50-4.

Specialty Tier-Level Cost Sharing and Biologic Agent Use in the Medicare Part D Initial Coverage Period Among Beneficiaries With Rheumatoid Arthritis.

Arthritis Care Res (Hoboken). 2016 Nov;68(11):1624-1630. doi: 10.1002/acr.22880.

Healthcare Reform: Enforcement and Compliance.

Issue Brief Health Policy Track Serv. 2016 Dec 27;2016:1-37.

Coverage for high-cost specialty drugs for rheumatoid arthritis in Medicare Part D.

Arthritis Rheumatol. 2015 Jun;67(6):1474-80. doi: 10.1002/art.39079.

Economic incentives and barriers to quality care.

Nephrol News Issues. 2007 May;21(6):5.

Medicare's e-prescribing incentive program. An introduction.

Adv Nurse Pract. 2009 May;17(5):49-50.

Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.

Arthritis Rheum. 2008 Apr;58(4):939-46. doi: 10.1002/art.23374.

JAMA PATIENT PAGE. Medicare.

JAMA. 2015 Jul 28;314(4):420. doi: 10.1001/jama.2015.8049.

引用本文的文献

Insurance Type Influences Access to Biologics and Healthcare Utilization in Pediatric Crohn's Disease.

Crohns Colitis 360. 2021 Aug 7;3(3):otab057. doi: 10.1093/crocol/otab057. eCollection 2021 Jul.

Identifying factors associated with concordance with the American College of Rheumatology rheumatoid arthritis treatment recommendations.

Arthritis Res Ther. 2016 Apr 26;18:94. doi: 10.1186/s13075-016-0992-3.

Dose modifications of anti-TNF drugs in rheumatoid arthritis patients under real-world settings: a systematic review.

Rheumatol Int. 2015 Jul;35(7):1193-210. doi: 10.1007/s00296-015-3222-4. Epub 2015 Feb 1.

本文引用的文献

Impact of the Medicare Modernization Act of 2003 on utilization and spending for medicare part B-covered biologics in rheumatoid arthritis.

Arthritis Care Res (Hoboken). 2010 Mar;62(3):354-61. doi: 10.1002/acr.20010.

Impact of Medicare Part D on access to and cost sharing for specialty biologic medications for beneficiaries with rheumatoid arthritis.

Arthritis Rheum. 2009 Jun 15;61(6):745-54. doi: 10.1002/art.24560.

Association between the Medicare Modernization Act of 2003 and patient wait times and travel distance for chemotherapy.

JAMA. 2008 Jul 9;300(2):189-96. doi: 10.1001/jama.300.2.189.

Biologic drugs for rheumatoid arthritis in the Medicare program: a cost-effectiveness analysis.

Arthritis Rheum. 2008 Apr;58(4):939-46. doi: 10.1002/art.23374.

The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?

Cancer. 2007 Nov 15;110(10):2304-12. doi: 10.1002/cncr.23042.

Medicare prescription drug benefit progress report: findings from a 2006 national survey of seniors.

Health Aff (Millwood). 2007 Sep-Oct;26(5):w630-43. doi: 10.1377/hlthaff.26.5.w630. Epub 2007 Aug 21.

A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.

Health Technol Assess. 2006 Nov;10(42):iii-iv, xi-xiii, 1-229. doi: 10.3310/hta10420.

Impact of the Medicare Prescription Drug Improvement and Modernization Act on the management of colorectal cancer.

Am J Health Syst Pharm. 2006 May 1;63(9 Suppl 2):S18-21. doi: 10.2146/ajhp060114.

Medicare coverage of tumor necrosis factor alpha inhibitors as an influence on physicians' prescribing behavior.

Arch Intern Med. 2006 Jan 9;166(1):57-63. doi: 10.1001/archinte.166.1.57.

Prescription drug coverage and seniors: findings from a 2003 national survey.

Health Aff (Millwood). 2005 Jan-Jun;Suppl Web Exclusives:W5-152-W5-166. doi: 10.1377/hlthaff.w5.152.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验